We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
The company has several interesting candidates in its pipeline. Its cancer pipeline comprises enasidenib (IDH2 mutant inhibitor), AG-120 (IDH1 mutant inhibitor) and AG-881 (pan-IDH mutant inhibitor).
Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-881.
With no approved products in its portfolio, investor focus should remain on the company’s pipeline updates since a number of pipeline-related activities are lined up for the rest of 2016.
Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average miss of 80.87%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agios posted wider-than-expected loss in the third quarter of 2016. Our consensus called for a loss of $1.51 per share, and the company reported a loss of $1.63.
Revenues: Revenues in the reported quarter also came in below expectations. Agios posted revenues of approximately $9 million, compared to our consensus estimate of $10.8 million.
Key Stats: Agios continues to progress with its pipeline. Agios along with Celgene will submit a new drug application for enasidenib for the treatment of patients with relapsed and/or refractory acute myeloid leukemia by the end of 2016.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agios (AGIO) Posts Wider-than-Expected Loss in Q3
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
The company has several interesting candidates in its pipeline. Its cancer pipeline comprises enasidenib (IDH2 mutant inhibitor), AG-120 (IDH1 mutant inhibitor) and AG-881 (pan-IDH mutant inhibitor).
Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-881.
With no approved products in its portfolio, investor focus should remain on the company’s pipeline updates since a number of pipeline-related activities are lined up for the rest of 2016.
Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average miss of 80.87%.
AGIOS PHARMACT Price and EPS Surprise
AGIOS PHARMACT Price and EPS Surprise | AGIOS PHARMACT Quote
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agios posted wider-than-expected loss in the third quarter of 2016. Our consensus called for a loss of $1.51 per share, and the company reported a loss of $1.63.
Revenues: Revenues in the reported quarter also came in below expectations. Agios posted revenues of approximately $9 million, compared to our consensus estimate of $10.8 million.
Key Stats: Agios continues to progress with its pipeline. Agios along with Celgene will submit a new drug application for enasidenib for the treatment of patients with relapsed and/or refractory acute myeloid leukemia by the end of 2016.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>